Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (May 2022)
43 slides from Adocia Sa's investor presentation, May 2022
Slide 1: Corporate Presentation May 2022
Corporate Presentation May 2022
Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those
Slide 3: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO R&D Director Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-founde
Slide 4: Executive Summary
Executive Summary Our mission: development of innovative formulations of approved 1 peptide and cell treatments for diabetes and obesity Our projects are based on 3 proprietary technologies: BioChaperone®, 2 AdOral®, AdoShell® with 4 products in clinical trials incl. 1 in phase 3 Business model: Lic
Slide 5: Adocia's partnering models: strategic pillars to ensure financial sustainability
Adocia’s partnering models: 2 strategic pillars to ensure financial sustainability Licensing Technology platforms Licensing Proprietary specialty products applied to pharma partner’s based on approved drugs proprietary products ✓ $50m upfront • BioChaperone LisproPartnered ✓ $5m BC Lispro FPI • AdOr
Slide 6: Both partnering models are based on proprietary technology platforms with strong IP strategy
Both Adocia’s partnering models are based on proprietary technology platforms with strong IP strategy BioChaperone® AdOral ® AdoShell ® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Forms a complex with therapeutic • Enhances proteins/peptides oral route • Encapsulation
Slide 7: Proprietary specialty products based on approved drugs
Proprietary specialty products based on approved drugs 7 7
Slide 8: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese • Several hormones are involved in both diabetes and obesity 1.9 billion
Slide 9: Adocia's vision of metabolic diseases treatment: from hormonal to cell therapies
Adocia’s vision of metabolic diseases treatment: from hormonal to cell therapies Immuno-protective scaffold for islets of Langerhans Oral Delivery of hormones Pluri-hormonal formulations Improved proteins/peptides formulations Adocia is taking on high challenges, that require innovative mindset and
Slide 10: A rich specialty product pipeline to maximize chances of success
A rich specialty product pipeline to maximize chances of success Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones BC Lispro Partnered Phase 3 in China ongoing Ultra-Rapid Insulin U100 / U200 for Asia Phase 3 in USA and Europe ready to start* Insulins Combination Partnered BC Combo U200
Slide 11: BioChaperone Lispro
BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control 11 11
Slide 12: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100
Slide 13: BC Lispro in phase 3 program in China and ready to start in ROW
BC Lispro in phase 3 program in China and ready to start in ROW • Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization
Slide 14: BC Combo, glargine-lispro premix
BC Combo, glargine-lispro premix The best insulin premix 14 14
Slide 15: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia Simple Affordable Less hypoglycemia Limited number of injections
Slide 16: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2.7bn1 Western Markets: T2D patients • $40m upfront $2.3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D • Double-digit royalties on sales ~65% patients Market share in India and China (volume)
Slide 17: Insulin & Amylin analogs combinations M1Pram and BC LisPram
Insulin & Amylin analogs combinations M1Pram and BC LisPram First-in-class combination products, the 5th generation of prandial insulin 17 17
Slide 18: Amylin hormone is missing in people with diabetes
Amylin hormone is missing in people with diabetes, and it contributes to diabetes dysregulations Meal Pancreas Insulin Normal pattern Level of secretion (relative scale) Amylin Insulin Glucagon Secreted 0 1 2 3 4 5 6 Co-secreted Glucagon by α-cells Time (hours) by β-cells Meal Level of secretion Glu
Slide 19: Pramlintide (Symlin), an amylin analog, has demonstrated its clinical benefits
Pramlintide (Symlin®), an amylin analog, has demonstrated its clinical benefits when associated with insulin and is FDA approved in T1D and T2D Pramlintide pharmacological effects Symlin limitations 1. Activates amylin receptors in different brain areas 1. 3 additional daily injections required on t
Slide 20: Adocia targets to replace insulin by bi-hormonal insulin therapies
Adocia targets to replace insulin by bi-hormonal insulin therapies Multi-hormonal Insulin/Pramlintide is the first prandial Medical combinations insulin able to improve: benefits M1Pram, BC LisPram ✓ HbA1c ✓ Time-in-Range Ultra-Rapid Insulins ✓ Weight loss BC Lispro, Fiasp®, Lyumjev® ✓ Well-being Ra
Slide 21: Adocia is developing one formulation for pen and one for pump
Adocia is developing one formulation for pen and one for pump Type Preclinic Phase 1 Phase 2 Phase 3 Upcoming Regular insulin Pramlintide Clinical Q2 2022 M1Pram POC Phase 2 T1D results in Pen (MDI) communication Rapid insulin Pramlintide Q3 2022 BC LisPram Phase 1 T1D pump study in Pump results MDI
Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog
Promising Phase 1b results of M1Pram in pen vs Novolog Results of phase 1b part B: 3-week outpatient trial - M1Pram vs. Novolog (n=16; High dose of insulin) Average glycemia Weight Time In Range After only 3 weeks: 164 16,2 0,5 162 0.4 16 ✓ Better post-prandial 0 15,8 glycemic control 160 -7 mg/dL 1
Slide 23: M1Pram in pen generates high expectations from KOLs
M1Pram in pen generates high expectations from KOLs ”By mimicking the normal co-secretion of amylin and “This combination has the potential to insulin with meals, this 2-in-1 combination has the finally deliver on the promise of pramlintide potential to address the persisting unmet need for for a la
Slide 24: BC LisPram: the optimal combination for pumps
BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, Adocia intends to reproduce A. Haidar POC with its fixed by Dr. Ahmad Haidar combination of Lispro and Pram delivered in one single pump Lispro in one pump vs. Lispro and Pramlintide ad
Slide 25: AdoShell islets to cure Type 1 Diabetes
AdoShell® islets to cure Type 1 Diabetes Immuno-protective scaffold for pancreatic islet transplant 25 25
Slide 26: AdoShell: An ultra-thin, immuno-protective hydrogel film for cell encapsulation
AdoShell® : An ultra-thin, immuno-protective hydrogel film for cell encapsulation High water content for cell compatibility ✓ Immuno-isolating gel ✓ Ultra-thin aseptic film ✓ High cell density for miniaturization ✓ Biocompatible ✓ Mechanically resistant ✓ Implantable by mini-invasive surgery ✓ Retri
Slide 27: Islets transplantation has changed lives of patients but still has limitations
Islets transplantation has changed lives of patients living with brittle T1D but still suffering from many limitations ❑ Among 40 million people live with T1D worldwide, 75 000 T1D are particularly unstable • Life expectancy 27- to 45-year-old • Approx. 1000 cases in France (3 T1D unstable/1000 T1D)
Slide 28: AdoShell, an immuno-protective scaffold for islets of Langerhans transplantation
Adocia has developed AdoShell®, an immuno-protective scaffold for islets of Langerhans transplantation for brittle diabetes Hydrogel Reagents Immuno-isolation AdoShell-Islets Film Ab, T cells Large entities > 10 nm + Insulin secreting cells 1st generation: Langerhans islets from deceased donors 2nd
Slide 29: Development is in progress
Development is in progress In vitro encapsulation results ✓ Human islets viable and functional ✓ Fast insulin delivery to glucose stimuli ✓ No infiltration of antibodies ✓ Simple aseptic and cell-friendly process In vivo transplantation results ✓ Control of the glycemia in diabetic rat at least 64 d
Slide 30: AdOral
AdOral® A promising technology for oral delivery of peptides 30 30
Slide 31: Only 5 peptide therapeutics approved for oral delivery in a growing market
Only 5 peptide therapeutics have been approved for oral delivery in a growing market dominated by injectable forms Global Peptide Therapeutics Market* ($) *mAb excluded from the analysis Cyclosporin 39 Billion 48 Billion 1.2 kDa Approved 1995 Voclosporin Octreotide 50 Desmopressin 1.2 kDa 1.0 kDa GL
Slide 32: AdOral: a promising technology for oral delivery of peptides
AdOral: a promising technology for oral delivery of peptides AdOral is a unique formulation based on a new type of permeation enhancer (PE)* combined with peptide protection against degradation AdOral form is a tablet or capsule Technology patented by Adocia The technology has been validated with Se
Slide 33: Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal
Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal Median Semaglutide PK Profile (N=10) Bioavailability of semagludide Rybelsus® formulated with AdOral: Adocia’s oral semaglutide 6.4-fold higher median than Rybelsus AdOral-Sema is under development aiming f
Slide 34: Obesity
Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” 34 34
Slide 35: Obesity, new therapies for a worldwide chronic pandemic
Obesity, new therapies for a worldwide chronic pandemic • 650 million adults are obese Recent therapeutic breakthroughs 1. Short acting GLP-1, Liraglutide • 1.9 billion are overweight (Saxenda® , Novo) 2. Long acting GLP-1, Semaglutide • Of the 42.4% Americans who are obese, (Wegovy®, Novo) up to 70
Slide 36: Patient-centric treatments with short-acting hormones delivered by a pump
Adocia is developing patient-centric treatments with short-acting hormones delivered by a pump DRUG-DEVICE COMBINATION « STOP-AND-GO » CONCEPT n days infusion n days infusion 1 day off Concentration The patient wears a patch-pump 4x to deliver combination of short acting hormones Concentration Expec
Slide 37: Combinations of diabetes hormones appear to be a revolutionary way to treat obesity
Combinations of “diabetes” hormones appear to be a revolutionary way to treat obesity Weight loss %* 0 Current marketed AMYLIN treatments 5 Diabetes GLP-1 Obesity Mono-hormonal 15 GLUCAGON 20 Multi-hormonal Time Adocia has selected a combination of Glucagon and Exenatide, two hormones with different
Slide 38: BioChaperone Glucagon Exenatide (BC GluExe)
BioChaperone® Glucagon Exenatide (BC GluExe) Proof-of-Concept established in obese mice 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showed a significant -25% w
Slide 39: Financial & news flow
Financial & news flow ADOCIA f
Slide 40: News flow
News flow BC Lispro M1Pram Hormonal combinations for obesity • In China (with partner THDB): • Phase 2 study in T1D in MDI • First-in-human study expected in Phase 3 ongoing (Multiple Daily Injection) 2023 completed • In USA/EU: Phase 3 ready to be launched upon partnership • Results communication i
Slide 41: Key financials & shareholder information
Key financials & shareholder information Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception • 7.8m shares outstanding • $120m received from partnerships • ADR program in the US (ADOCY) Soula Family 20,7%
Slide 42: Summary
Summary • Adocia’s projects are based on 3 proprietary technologies: BioChaperone®, AdOral®, AdoShell® • A well-advanced and diversified pipeline with products ready-to-license: • 4 products in ongoing clinical trials: o BC Lispro Phase 3 clinical trial in China o BC Combo clinical trials for qualif
Slide 43: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com